(Q37602291)

21 August 2017

1 reference

title

Chemotherapy, which drugs and when (English)

1 reference

21 August 2017

1 reference

Miriam Koopman

1

1 reference

21 August 2017

Cornelis J A Punt

series ordinal

2

1 reference

21 August 2017

language of work or name

1 reference

1 September 2009

1 reference

European Journal of Cancer

21 August 2017

published in

1 reference

21 August 2017

volume

45 Suppl 1

1 reference

21 August 2017

page(s)

50-56

1 reference

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

New options and old dilemmas in the treatment of patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Oxaliplatin: a review of preclinical and clinical studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

The CAIRO and FOCUS studies: which lesson is to be learned?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

1 reference

7 January 2021

Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic O

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Potential regional differences for the tolerability profiles of fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Current questions in the treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Complete response of colorectal liver metastases after chemotherapy: does it mean cure?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Deficient mismatch repair system in patients with sporadic advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Predictive factors for response to chemotherapy in colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970016-4

7 January 2021

10.1016/S0959-8049(09)70016-4

Identifiers

DOI

1 reference

21 August 2017

1 reference